QSAR model for drug human oral bioavailability

Journal of Medicinal Chemistry

Volumn 43, Issue 13, 2000, Pages 2575-2585

  Yoshida, Fumitaka ^a,b   Topliss, John G ^b  

^a KUMIAI CHEMICAL INDUSTRY CO LTD   (Japan)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; ALPRENOLOL; CLOMETHIAZOLE; COUMARIN; DOBUTAMINE; DOMPERIDONE; DOPAMINE; EPANOLOL; ESTRADIOL; FELODIPINE; HYDRALAZINE; ISRADIPINE; KETAMINE; LOFEPRAMINE; MEBENDAZOLE; MEPTAZINOL; MERCAPTOPURINE; MEVINOLIN; NABUMETONE; NALBUPHINE; NALOXONE; NIMODIPINE; NISOLDIPINE; NITRENDIPINE; PHENOLPHTHALEIN; PROBUCOL; PROCHLORPERAZINE; PROGESTERONE; SELEGILINE; UNINDEXED DRUG;

ARTICLE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG METABOLISM; LIPOPHILICITY; MODEL; PH; PHYSICAL CHEMISTRY; QUANTITATIVE STRUCTURE ACTIVITY RELATION;

ADMINISTRATION, ORAL; BIOLOGICAL AVAILABILITY; HUMANS; MODELS, BIOLOGICAL; MODELS, MOLECULAR; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0034729673     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0000564     Document Type: Article

References (38)

1. Presented in part at the Corwin Hansch Award Symposium, Division of Computers in Chemistry, ACS National Meeting, Anaheim, CA, March 21-25, 1999.
2. Austel, V.; Kutter, E. In Quantitative Structure-Activity Relationships of Drugs; Topliss J. G., Ed.; Academic Press: New York, 1983; pp 437-496.
3. Lien, E. J. In Drug Design; Ariens, E. J., Ed.; Academic Press: New York, 1975; Vol V, Chapter 3.
4. Hansch, C.; Leo, A.; Hoekman, D., Eds.: Exploring QSAR-Fundamentals and Applications in Chemistry and Biology; American Chemical Society: Washington, DC, 1995; Chapter 8.
5. Hirono, S,; Nakagome, I.; Hirano, H.; Matsushita, Y.; Yoshi, F.; Moriguchi, I. Noncongeneric structure-pharmacokinetic property correlation studies using fuzzy adaptive least-squares: Oral bioavailability. Biol. Pharm. Bull 1994, 17 (2), 306.
6. Kubinyi, H. QSAR: Hansch Analysis and Related Approaches: Methods and Principles in Medicinal Chemistry; Mannhold, R., Krogsgaard-Larson, P., Timmerman, H., Eds.; VCH: Weinheim, 1993; Vol 1, pp 100-101.
7. (a) Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed.; Hardman, J. G., Limbird, L. E., Molinoff, P. B., Ruddon, R. W., Gilman, A. G., Eds.; McGraw-Hill: New York, 1996: pp 1712-1792.
8. (b) Handbook of Clinical Pharmacology; Bochner, F., Carruthers, G., Kampman, J., Steiner, J., Azarnoff, D. L., Eds.; Little, Brown and Company: Boston/ Toronto 1983.
9. (c) Clin. Pharmacokinet. 1990-1994, 18-25.
10. (d) Handbook of Clinical Pharmacokinetic Data; Jack, D. B., Ed.; Macmillan: New York, 1992.
11. (e) Physicians Desk Reference, 53rd ed., Medical Economics Co.: 1999.
12. Hansch, C.; Leo, A.; Hoekman, D. Exploring QSAR-Hydrophobic, Electronic and Steric Constants; American Chemical Society: Washington, DC, 1995.
13. CLOGP program, ver. 1.0.0, Biobyte Corp.
14. Moriguchi, I.; Hirono, S.; Liu, Q.; Nakagome, I.; Matsushita, Y. Simple method of calculating octanol/water partition coefficient. Chem. Pharm. Bull. 1992, 40 (1), 127-130.
15. Scherrer, R. A.; Howard, S. M. Use of distribution coefficients in quantitative structure-activity relationships. J. Med. Chem. 1977, 20, 53-58.
16. (a) Wilson and Grisvold's Textbook of Organic Medicinal and Pharmaceutical Chemistry, 9th ed.; Delgado, J. N., Remers, W. A., Eds.; J. B. Lipincott: Philadephia, 1991; pp 877-881.
17. (b) AHFS 94 Drug Information; American Society of Hospital Pharmacists, Inc.: 1994.
18. (c) Principles of Medicinal Chemistry, 4th ed.; Foye, W. O., Lemke, T. L., Williams, D. A., Eds.; Williams and Wilkins: Baltimore, 1995; pp 948-960.
19. (d) The Merck Index, 12th ed., Budavari, S., Ed.; Merck & Co., Inc.: Whitehouse Station, NJ, 1996.
20. (e) Physicians Desk Reference, 52-54nd eds.; Medical Economics Co.: 1998-2000.
21. Dressman, J. B.; Amidon, G. L.; Fleisher, D. J. Absorption potential: Estimating the fraction absorbed for orally administered compounds. J. Pharm. Sci. 1985, 74, 588-589.
22. Takahashi, Y.; Miyashita, Y.; Abe, H.; Sasaki, S. A new approach for ordered multicategorical classification using simplex technique. Bunseki Kagaku 1984, 33, E487-E494.
23. Sasaki, S.; Takahashi, Y. Application of pattern recognition techniques to assessment of hazards of chemical substances. Hazard Asses. Chem. 1986, 5, 61-101.
24. Takahashi, Y.; Sasaki, S. Application of the ORMUCS method to structure-activity studies on the fungicidal activity of mepronil derivatives. Quant. Struct.-Act. Relat. 1987, 6, 17-21.
25. Lien, E. J. Structure-activity relationships and drug disposition. Ann. Rev. Pharmacol. Toxicol. 1981, 21, 31-61.
26. Lipinsky, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 1997, 23, 3-25.
27. Zimm, S.; Collins, J. M.; O'Neill, D.; Chabner, B. A.; Poplack, D. G. Inhibition of first-pass metabolism in cancer chemotherapy: Interaction of 6-mercaptopurine and allopurinol. Clin. Pharmacol. Ther. 1983, 34, 810-817.
28. Nogami, H.; Hanano, M.; Yamada, H. Studies on absorption and excretion of drugs. X. Relation between chemical structure and absorption rate. (2). Substituent constant for absorption rate coefficient of foreign organic compounds.Chem. Pharm. Bull. 1968, 16, 580-585.
29. Tai, A. W.; Lien, E. J. Structure-activity relationship in membrane transport and drug absorption. Acta Pharm. Jugoslav. 1980, 30, 171-182.
30. Burton, P. S.; Conradi, R. A.; Hilgers, A. R. (B) Mechanisms of peptide and protein absorption. (2) Transcellular mechanisms of peptide and protein absorption: Passive aspects. Adv. Drug Del. Rev. 1991, 7, 365-386.
31. von Geldern, T. W.; Hoffman, D. J.; Kester, J. A.; Nellans, H. N.; Dayton, B. W.; Calzadilla, S. V.; Marsh, K. C.; Hernandez, L.; Chiou, W.; Dixon, D. B.; Wu-Wong, J. R.; Opgenorth, T. J. Azole endothelin antagonists. 3. using Δ log P as a tool to improve absorption. J. Med. Chem. 1996, 39, 982-991.
32. (a) Walle, T.; Gaffney, T. E. Propanolol metabolism in man and dog: Mass spectrometric identification of six new metabolites. J. Pharmacol. Exptl. Ther. 1972, 182, 83-92.
33. (b) Reference 12c, p 136.
34. Debnath, A. K.; Debnath, G.; Shusterman, A. J.; Hansch, C. A QSAR investigation of the role of hydrophobicity in regulating mutagenicity in the Ames test. 1. Mutagenicity of aromatic and heteroaromatic amines in Salmonella typhimurium TA98 and TA100. Environ. Mol. Mutagen. 1992, 19, 37-52.
35. Hansch, C. Quantitative relationships between lipophilic character and drug metabolism. Drug Metab. Rev. 1972, 1, 1-13.
36. Hansch, C.; Steward, A. R.; Iwasa, J. The use of substituent constants in the correlation of demethylation rates. J. Med. Chem. 1965, 8, 868-870.
37. Beckett, A. H.; Shenoy, E. V. B.; Salmon, J. A. The influence of replacement of the N-ethyl group by the cyanoethyl group on the absorption, distribution and metabolism of (±)-ethylamphetamine. J. Pharm. Pharmacol. 1972, 24, 194-202.
38. Reference 7a, Chapter 51, p 1250.